Ascendis Pharma A/S (NASDAQ:ASND) Upgraded to “Strong-Buy” at Citigroup

Posted by Brenda Bartman on May 20th, 2026

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) was upgraded by equities researchers at Citigroup to a “strong-buy” rating in a research note issued on Monday,Zacks.com reports.

Other equities research analysts have also issued research reports about the stock. Royal Bank Of Canada raised their target price on shares of Ascendis Pharma A/S from $250.00 to $275.00 and gave the stock an “outperform” rating in a report on Monday, March 2nd. Cantor Fitzgerald restated an “overweight” rating and issued a $300.00 target price on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Wall Street Zen upgraded shares of Ascendis Pharma A/S from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Morgan Stanley reiterated an “overweight” rating and set a $256.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, February 12th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $255.00 price objective on shares of Ascendis Pharma A/S in a report on Monday, March 2nd. Two investment analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $295.39.

View Our Latest Analysis on ASND

Ascendis Pharma A/S Price Performance

Ascendis Pharma A/S stock opened at $237.96 on Monday. The firm has a 50-day moving average price of $232.12 and a 200-day moving average price of $221.06. The firm has a market capitalization of $14.84 billion, a PE ratio of 27.45 and a beta of 0.41. The company has a current ratio of 1.00, a quick ratio of 0.72 and a debt-to-equity ratio of 0.79. Ascendis Pharma A/S has a 12-month low of $153.49 and a 12-month high of $250.74.

Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) last released its earnings results on Thursday, May 7th. The biotechnology company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.21 by $0.11. The firm had revenue of $285.45 million during the quarter, compared to the consensus estimate of $362.47 million. As a group, equities research analysts forecast that Ascendis Pharma A/S will post 12.19 EPS for the current year.

Insider Activity at Ascendis Pharma A/S

In other news, insider Flemming Steen Jensen sold 19,460 shares of the business’s stock in a transaction dated Monday, May 11th. The shares were sold at an average price of $238.49, for a total value of $4,641,015.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 40.00% of the company’s stock.

Institutional Investors Weigh In On Ascendis Pharma A/S

Several large investors have recently modified their holdings of the business. Avoro Capital Advisors LLC raised its holdings in shares of Ascendis Pharma A/S by 2.6% in the 3rd quarter. Avoro Capital Advisors LLC now owns 5,110,000 shares of the biotechnology company’s stock valued at $1,015,919,000 after purchasing an additional 130,000 shares in the last quarter. Capital International Investors raised its holdings in shares of Ascendis Pharma A/S by 0.4% in the 3rd quarter. Capital International Investors now owns 3,060,616 shares of the biotechnology company’s stock valued at $608,481,000 after purchasing an additional 13,685 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Ascendis Pharma A/S by 95.9% in the 3rd quarter. Wellington Management Group LLP now owns 1,798,931 shares of the biotechnology company’s stock valued at $357,645,000 after purchasing an additional 880,836 shares in the last quarter. Principal Financial Group Inc. raised its holdings in shares of Ascendis Pharma A/S by 29.3% in the 4th quarter. Principal Financial Group Inc. now owns 1,026,407 shares of the biotechnology company’s stock valued at $218,871,000 after purchasing an additional 232,730 shares in the last quarter. Finally, Perceptive Advisors LLC purchased a new position in shares of Ascendis Pharma A/S in the 2nd quarter worth approximately $166,367,000.

About Ascendis Pharma A/S

(Get Free Report)

Ascendis Pharma A/S is a Denmark‐based biopharmaceutical company focused on developing innovative therapies for rare endocrine diseases. Founded in 2015 and headquartered in Hellerup, the company leverages its proprietary TransCon drug delivery platform to create long‐acting prodrugs designed to improve safety, efficacy and patient convenience. Ascendis Pharma maintains research and development operations in Europe and the United States, with clinical studies spanning North America, Europe and Asia.

The company’s lead product, lonapegsomatropin (Skytrofa®), is a once‐weekly growth hormone therapy approved by the U.S.